CD172A抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Ramos cells using CD172A mouse mAb (green) and negative control (red).    

  
  

CD172A, also known as SIRPα (Signal Regulatory Protein α), is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is predominantly expressed on myeloid cells, including dendritic cells, macrophages, and neutrophils, as well as some neuronal cells. Structurally, CD172A features three extracellular immunoglobulin-like domains (one V-type and two C1-type), a transmembrane region, and a cytoplasmic tail containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Its primary function involves modulating immune responses through interaction with CD47. a widely expressed "don't eat me" signal ligand. The CD172A-CD47 axis delivers inhibitory signals that regulate phagocytosis, T-cell activation, and immune tolerance, thereby maintaining homeostasis and preventing autoimmunity.

CD172A antibodies are critical tools in studying immune checkpoint regulation, particularly in cancer immunotherapy. Blocking CD172A-CD47 interactions with monoclonal antibodies (e.g., clones SE5A5 or P84) has shown potential to enhance phagocytic clearance of tumor cells and synergize with antitumor therapies. These antibodies are also used in flow cytometry and immunohistochemistry to identify myeloid cell subsets. Recent research explores their role in inflammatory diseases, neuroimmunology, and hematopoietic stem cell regulation. Variants in CD172A genes or dysregulated expression have been linked to autoimmune disorders and cancer progression, underscoring its therapeutic relevance. Ongoing studies aim to optimize antibody specificity (blocking vs. non-blocking epitopes) and evaluate clinical safety in targeting this pathway.